Interneuron and motoneuron properties in chronic spinal injury

Information

  • Research Project
  • 8670031
  • ApplicationId
    8670031
  • Core Project Number
    R01NS047567
  • Full Project Number
    5R01NS047567-10
  • Serial Number
    047567
  • FOA Number
    PA-07-070
  • Sub Project Id
  • Project Start Date
    12/1/2003 - 21 years ago
  • Project End Date
    2/29/2016 - 8 years ago
  • Program Officer Name
    JAKEMAN, LYN B
  • Budget Start Date
    6/1/2014 - 10 years ago
  • Budget End Date
    2/29/2016 - 8 years ago
  • Fiscal Year
    2014
  • Support Year
    10
  • Suffix
  • Award Notice Date
    5/5/2014 - 10 years ago
Organizations

Interneuron and motoneuron properties in chronic spinal injury

DESCRIPTION (provided by applicant): Serotonin (5-HT) is a potent neuromodulator that regulates the spinal cord motoneurons, interneurons and sensory afferents involved in controlling posture and movement. 5-HT facilitates motoneuron excitability in part by activating Gq-protein-coupled 5-HT2 receptors that facilitate persistent calcium and sodium currents (persistent inward currents, or PICs), which in turn markedly amplify and prolong the motoneuron response to synaptic inputs. Because 5-HT arises mostly from the brainstem, spinal cord injury dramatically reduces 5-HT levels below the injury, and thus, immediately after injury PICs become small and motor output is accordingly severely weakened. However, the PICs undergo a remarkable recovery over the ensuing months after injury, becoming very large, despite the continued absence of most 5-HT below the injury. These large PICs play an important role in the recovery of residual motor function after chronic injury, and at the same time cause excess motoneuron activity that is manifested as severe muscle spasms. Thus, understanding what causes this spontaneous recovery of PICs and general motoneuron excitability is both important for understanding recovery of motor function and treating muscle spasms, the focus of our research. This proposal investigates the novel idea that the recovery of motoneuron PICs after chronic spinal cord injury may result from 5-HT2 receptors that become constitutively active, that is, spontaneously entering into their active state and initiating Gq-protein-mediated signaling without binding of 5-HT (Aim 1). In contrast, other 5-HT receptors that also modulate spinal cord excitability may not change with chronic spinal cord injury, and this is investigated in Aims 2 and 3 as follows. Normally, 5-HT regulates dorsal horn interneurons and associated sensory afferent transmission via Gi-coupled 5HT1 receptors. Loss of 5-HT with spinal cord injury causes an immediate loss of inhibition over afferent transmission, but this transmission is not restored to normal with chronic injury, suggesting that the 5-HT1 receptors do not compensate for lost 5-HT with constitutive activity. 5-HT also regulates the motoneuron membrane resting potential via Gs-coupled 5-HT6 (and 5-HT7) receptors, and likewise , membrane potential does not change with chronic, compared to acute, spinal cord injury, suggesting again that these 5-HT6 receptors do not become constitutively active with chronic injury. The final experiments (of Aim 4) examine the potential clinical application of Aims 1 - 3. These experiments explore whether drugs that modulate 5-HT2, 5-HT1 and 5-HT6 receptor activity (and associated PICs, afferent transmission and resting potential) can be used to help restore near-normal levels of postural tone and reflex patterns, while reducing muscle spasms. In summary, constitutive receptor activity provides an entirely new mechanism to explain spontaneous recovery of motor function after injury. Modulation of this constitutive receptor activity (or lack of activity) provides a novel approach to treating spasticity while restoring lost motor function.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R01
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    263923
  • Indirect Cost Amount
    9605
  • Total Cost
    273528
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:273528\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CNNT
  • Study Section Name
    Clinical Neuroplasticity and Neurotransmitters Study Section
  • Organization Name
    UNIVERSITY OF ALBERTA
  • Organization Department
  • Organization DUNS
    208095844
  • Organization City
    EDMONTON
  • Organization State
    AB
  • Organization Country
    CANADA
  • Organization Zip Code
    T6G 2E1
  • Organization District
    CANADA